Major adverse cardiovascular events and hyperuricemia as an effect-modifying factor in kidney transplant recipients

Table 2 Univariate relationships between having major adverse cardiovascular events and independent variables, n (%)

Variable	Without MACEs (n = 400)	With MACEs (n = 145)	P value
Male gender	202 (71.4)	81 (28.6)	0.29
Age, mean (SD) (years)	50.7 (14.5)	60.9 (12.3)	< 0.01
Body mass index, mean (SD) (kg/m2)	25.4 (4.5)	26.7 (4.5)	< 0.01
Current smokers	106 (64.2)	59 (35.8)	< 0.01
Having hypertension	332 (70.0)	142 (30.0)	< 0.01
Having left ventricular hypertrophy	288 (66.8)	143 (33.2)	< 0.01
Having dyslipidemia	302 (70.9)	124 (29.1)	0.01
Having previous cardiovascular events	5 (1.3)	74 (93.7)	< 0.01
Uric acid,mean (SD) (μmol/L)	411.26 (89.6)	520.0 (102.5)	< 0.01
Glomerular filtration rate, mean (SD) (mL/minute)	49.6 (25.1)	37.7 (21.4)	< 0.01
Having proteinuria	103 (59.9)	69 (40.1)	< 0.01
Using steroids for more than one year	305 (74.2)	106 (25.8)	0.50
Acute rejection	135 (74.2)	47 (25.8)	0.84
Receiving hyperuricemia treatment	105 (55.0)	86 (45.0)	< 0.01
Receiving cyclosporine therapy	71 (64.0)	40 (36.0)	0.02
Receiving tacrolimus therapy	312 (77.2)	92 (22.8)	< 0.01
New onset of diabetes mellitus	55 (67.1)	27 (32.9)	0.32
Length of hemodialysis, mean (SD) (months)	16.9 (17.4)	20.2 (18.4)	< 0.01
Hyperparathyroidism, mean (SD) (pg/mL)	150.9 (137.5)	173.2 (112.1)	< 0.01
Inflammation, mean (SD) (mg/L)	4.3 (8.5)	5.9 (6.1)	< 0.01
Having anemia	110 (61.1)	70 (38.9)	< 0.01

MACEs: Major adverse cardiovascular events.